A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules

被引:238
作者
Choonara, Bibi F. [1 ]
Choonara, Yahya E. [1 ]
Kumar, Pradeep [1 ]
Bijukumar, Divya [1 ]
du Toit, Lisa C. [1 ]
Pillay, Viness [1 ]
机构
[1] Univ Witwatersrand, Sch Therapeut Sci, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol,Fac Hlth Sci, ZA-2193 Parktown, South Africa
关键词
Oral drug delivery; Therapeutic proteins and peptides; Bioavailability; Gastrointestinal barrier; Advanced oral biotechnology; CELL-PENETRATING PEPTIDES; ENHANCED INTESTINAL-ABSORPTION; CARRIER-MEDIATED TRANSPORT; BORDER MEMBRANE-VESICLES; BETA-LACTAM ANTIBIOTICS; IN-OIL MICROEMULSIONS; THERAPEUTIC PEPTIDES; TRANSDERMAL DELIVERY; COLONIC-RELEASE; INSULIN;
D O I
10.1016/j.biotechadv.2014.07.006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The oral delivery of proteins and peptides is a dynamic research field despite the numerous challenges limiting their effective delivery. Successful oral delivery of proteins and peptides requires the accomplishment of three key tasks: protection of the macromolecules from degradation in the gastrointestinal tract (GIT), permeation through the intestinal barrier and absorption of molecules into the systemic circulation. Currently, no clinically useful oral formulations have been developed but several attempts have been made to overcome the challenges of low oral bioavailability resulting from poor absorption, poor permeation and enzymatic degradation of the proteins and peptides in the GIT. Present strategies attempt to provide structural protection of the proteins and peptides and improved absorption through the use of enzyme inhibitors, absorption enhancers, novel polymeric delivery systems and chemical modification. However, each of these technologies has their limitations despite showing positive results. This review attempts to discuss the physical and chemical barriers of the GIT with particular emphasis on the current approaches employed to overcome these barriers, including the evaluation of other non-parenteral routes of protein and peptide delivery. In addition, this review assimilates oral formulation strategies under development and within the clinical trial stage in relation to their benefits and drawbacks with regard to facilitating optimal protection and absorption of proteins and peptides, as well as pertinent future challenges and opportunities governing oral drug delivery. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1269 / 1282
页数:14
相关论文
共 177 条
[51]   Protein delivery for retinal diseases: From basic considerations to clinical applications [J].
El Sanharawi, M. ;
Kowalczuk, L. ;
Touchard, E. ;
Omri, S. ;
de Kozak, Y. ;
Behar-Cohen, F. .
PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (06) :443-465
[52]   Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects [J].
Eldor, R. ;
Kidron, M. ;
Arbit, E. .
DIABETES OBESITY & METABOLISM, 2010, 12 (03) :219-223
[53]   Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study [J].
Eldor, Roy ;
Arbit, Ehud ;
Corcos, Asher ;
Kidron, Miriam .
PLOS ONE, 2013, 8 (04)
[54]  
Emisphere Technology Inc. Eligen&REG
[55]  
Technology, 2014, EL TECHN
[56]  
Enteris BioPharma Inc Peptelligence&TRADE
[57]  
technology, 2014, PEPT TECHN
[58]  
Fawzi MB, 1991, United States Patent, Patent No. [US 5068110 A, 5068110]
[59]   EXPRESSION CLONING OF A MAMMALIAN PROTON-COUPLED OLIGOPEPTIDE TRANSPORTER [J].
FEI, YJ ;
KANAI, Y ;
NUSSBERGER, S ;
GANAPATHY, V ;
LEIBACH, FH ;
ROMERO, MF ;
SINGH, SK ;
BORON, WF ;
HEDIGER, MA .
NATURE, 1994, 368 (6471) :563-566
[60]   New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut [J].
Fiorino, G. ;
Fries, W. ;
De La Rue, S. A. ;
Malesci, A. C. ;
Repici, A. ;
Danese, S. .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (17) :1851-1857